Guggenheim raised its price target for Ardent Health to $21 from $14 after the company's latest earnings report.

Nov 11, 2026, 7:38 AM ETOpinionRead the original at marketscreener.com

Good for ARDT

Guggenheim raised its share-price target from $14 to $21 and kept its Buy view, signaling a more favorable view of Ardent's shares. The report gives no new company results, so the positive read rests on that opinion.

ARDT · Ardent Health, Inc.

AI read · Good for ARDT

The AI's read

The higher target and unchanged Buy view show that Guggenheim sees more room for Ardent's shares. This is a favorable change in the firm's opinion, not a new change to Ardent's sales or profit. The report gives no details from the third-quarter results, so this read rests on the analyst's view alone.

Get alerts for ARDT

Follow Ardent Health, Inc. (ARDT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ARDT

Free on the App Store and Google Play, or on the web.